Transforming healthcare starts with the right people.

Andrew Conrad, PhD, is the Chief Executive Officer, Chairman and Founder of Verily where he oversees an integrated team of engineers, scientists, designers, and medical experts working on a wide spectrum of healthcare-related projects. Previously, he was Chief Scientific Officer of Laboratory Corporation of America (LabCorp). Dr. Conrad co-founded the National Genetics Institute, where he served as Chief Scientific Officer. He is a Working Group Member on the Precision Medicine Initiative and a member of the UCSF-Stanford Center of Excellence in Regulatory Science and Innovation (CERSI) Scientific Advisory Board.

Deepak Ahuja joined Verily in 2020 as Chief Financial Officer.  Previously, he served as CFO of Tesla from 2008 to 2015 and from 2017 to 2019. Deepak was Tesla’s first finance chief and helped guide it through its IPO in addition to raising several billion dollars of capital to fuel its growth. Prior to Tesla, he was at Ford Motor Company for 15 years, which provided him experiences in manufacturing, marketing & sales, product development, treasury and acquisitions/divestitures. Deepak holds an MS in industrial administration from Carnegie Mellon University, an MS in materials engineering from Northwestern University and a B Tech in ceramic engineering from Banaras Hindu University in India.

Scott Burke is the Chief Technology Officer at Verily, leading the software engineering organization and driving the development of innovative platforms powering applications in precision medicine, population health, health data sensors and care management. Prior to Verily, Scott was Co-founder and Chief Technology Officer for Helix. Before Helix, Scott worked for nine years at Yahoo, most recently as Senior Vice President of Advertising and Data Platforms. Prior to Yahoo, Scott led engineering teams at two mobile startups, Seven Networks and PacketHop, and was Vice President of Engineering for WebMD. Scott started his career as a computational physicist at Hewlett-Packard. He holds a bachelor’s degree in physics from Harvey Mudd College in Claremont, California.

Robert M. Califf, MD, MACC, is the Head of Clinical Policy and Strategy for Verily and Google Health. Prior to this Dr. Califf was the vice chancellor for health data science for the Duke University School of Medicine; director of Duke Forge, Duke’s center for health data science; and the Donald F. Fortin, MD, Professor of Cardiology. He served as Deputy Commissioner for Medical Products and Tobacco in the U.S. Food and Drug Administration (FDA) from 2015-2016, and as Commissioner of Food and Drugs from 2016-2017. A nationally and internationally recognized leader in cardiovascular medicine, health outcomes research, healthcare quality, and clinical research, Dr. Califf is a graduate of Duke University School of Medicine. Dr. Califf was the founding director of the Duke Clinical Research Institute and is one of the most frequently cited authors in biomedical science.

Stephen Gillett is the Chief Operating Officer at Verily, where he oversees engineering, business and commercial operations. Stephen was co-founder and CEO of Chronicle, an Alphabet cybersecurity company that is now part of Google Cloud. He is an active advisor to GV and X. Previously, Stephen served as EVP, COO and board member at Symantec, a Fortune 500 Enterprise Technology Company. He has also served as the EVP and president of Best Buy Digital and Business Operations, and was part of the founding Starbucks transformation leadership team as chief information officer and general manager of Digital Ventures. Stephen sits on the board of directors for University of Oregon, Phil and Penny Knight Campus for Accelerating Scientific Impact, and for Discord. He holds an MBA from San Francisco State University and a BS from the University of Oregon.

Lisa Greenbaum is the Chief Revenue Officer at Verily, where she is responsible for all commercial revenue generating activities across the organization including sales, business development, alliance management, sales operations and other sales-related activities and teams. Prior to Verily, Lisa was Chief Client Officer at Progyny where she led sales, account management, and channel partnerships. She joined Progyny prior to the IPO and was a key contributor to the company’s growth during her tenure. Before Progyny, Lisa spent 15 years at WebMD where she was Group General Manager of Medscape Professional Services and led sales, account management, product marketing and revenue delivery. Lisa has also held senior sales roles in the pharmaceutical and digital health space at HealthStream, Merck, and Procter & Gamble. She holds a bachelor’s degree from Duke University.

Vivian S. Lee, MD, PhD, MBA, works closely with Verily's clinical and engineering teams to develop products and platforms that support health system improvement and advance population health. She oversees all healthcare platforms, including Onduo, Healthy at Work and Verily's Value Suite, among others. Dr. Lee is the author of The Long Fix: Solving America's Health Care Crisis with Strategies that Work for Everyone (Norton, 2020). As a healthcare executive, she formerly served as the medical school dean, SVP, and CEO of the University of Utah Health, a $3.5 billion integrated health system and health plan that ranked first among university hospitals in quality and safety. A Rhodes Scholar, she is a graduate of Harvard College, Oxford University, Harvard Medical School and NYU Stern School of Business.

Jessica L. Mega, MD, MPH, is the Chief Medical and Scientific Officer at Verily. As CMSO, Dr. Mega's focus is on translating technological innovations and scientific insights into partnerships and programs that improve patient outcomes. As a faculty member at Harvard Medical School, a senior investigator with the TIMI Study Group, and a cardiologist at Brigham and Women's Hospital, she led large, international, randomized trials evaluating novel cardiovascular therapies. Dr. Mega is a graduate of Stanford University, Yale University School of Medicine and Harvard School of Public Health. She completed Internal Medicine Residency at Brigham and Women's Hospital and Cardiovascular Fellowship at Massachusetts General Hospital.

As a Fellow at Verily, Brian pushes the frontier of medical device innovation, leading the company's discovery and rapid prototyping efforts. He joined Verily from the University of Washington Department of Electrical Engineering where he was an Associate Professor. Previously, Brian held positions at the University of Washington Kelly Tremblay Brain and Behavior Laboratory, the UC-Berkeley Ralph Freeman Neuroscience Lab, The Berkeley Wireless Research Center, Intel Corporation and Agilent Laboratories. He received his MS and PhD in Electrical engineering in the field of low power integrated circuits for wireless sensors from the University of California, Berkeley.

Drew is the Chief Marketing Officer at Verily where he is responsible for all brand, digital and product marketing efforts, as well as overall marketing operations. Drew is currently an advisory board member to Swire Coca Cola USA, one of the country’s largest beverage companies. Drew draws upon his insight from more than 28 years of experience in leadership roles with companies including Johnson & Johnson, Hershey’s, Coca-Cola, Best Buy, The Walt Disney Company and BBDO. Previously, Drew was President of Red Wagon Ventures within Chick-fil-A where he led the development of new retail concepts and growth platforms. He has also led strategic investments in new start-ups as a lead in Engage Ventures. Drew graduated summa cum laude from Boston College, and received his MBA in Marketing and degree in Health Care Sector Management at Duke University, where he was a Fuqua Scholar.

Jordi leads Verily's medical devices business, combining hardware with software and machine learning to create differentiated product solutions that support Verily's research and health platforms, as well as external partnerships and joint ventures. Areas of interest include wearable monitoring sensors, diagnostics, surgical robotics, bioelectronics, ophthalmology and drug delivery devices. Jordi has more than 20 years of experience in the Medical Devices industry including a 12-year tenure at Boston Scientific before joining Verily. Jordi has authored more than 60 distinct patent families with 200+ granted patents worldwide. He holds a BS degree in Physics from the Universitat Autònoma de Barcelona and BS, MS and PhD degrees in Electrical Engineering from the National Center for Microelectronics of Spain at the Universitat Autònoma de Barcelona.

Cynthia Patton, JD, joined Verily in 2020 as General Counsel. Previously, she served as senior vice president and chief compliance officer at Amgen, where she was responsible for Amgen’s global privacy and compliance organization. She also served as chair of the Amgen Foundation. Prior to Amgen, she served as general counsel of SCAN Health Plan, a California Health Maintenance Organization (HMO). Cynthia received her JD from George Washington University and her bachelor’s degree from Vassar College, and is admitted to the State Bar of California, State Bar of Georgia and the District of Columbia Bar.

Preston Simons is the Chief Information Officer at Verily where he is responsible for building out our IT strategies, systems and processes. Previously, Preston was President and Managing Partner of Simons & Associates, LLC where he consulted companies on driving business value through transformation of organizational practices, business processes and technology alignment and implementation. He also specialized in merger and acquisition planning and coordination, IT transformation, integration and technology strategy engagement. Preston has served in C-level positions for several decades across companies such as Aurora Healthcare, Abbott Laboratories (a Fortune 100 life sciences and medical device company), and Smithkline Beecham (GSK). He is a member of the Board of Governors for the Opus College of Business at the University of St. Thomas, Minnesota, and is an Advisory Board member for Infinity Systems, Inc. He is a certified Board Leadership Fellow of the National Association of Corporate Directors. Preston earned his MBA from the Booth School of Business at the University of Chicago, and a BS degree in Management and Computer Science from the Illinois Institute of Technology.

Linus Upson joined Google in 2005 and leads Verily's Debug Project. Previously, he was responsible for overseeing Google's browser products including Chrome and Chrome OS. Prior to Google, Linus was an engineer at NeXT and Netscape and co-founded two companies, AvantGo and Qurb. Linus is on an extended leave from his undergraduate studies in mathematics at Princeton University.

Dimitri Azar, MD, MBA, is the Chief Executive Officer for Twenty/Twenty Therapeutics and former Dean of the University of Illinois College of Medicine. Dimitri is an ophthalmic surgeon who has made significant contributions to the treatment of corneal diseases and to advances in refractive surgery. He has served as a key adviser on Verily ophthalmic projects since 2014. Dimitri completed his residency and fellowship at the Massachusetts Eye and Ear Infirmary, Harvard Medical School. He was Professor of Ophthalmology at Harvard Medical School before joining the University of Illinois as Head of the Ophthalmology Department. Dimitri received his MD from American University of Beirut and his MBA from University of Chicago, Booth School of Business.

Kristoffer Famm is president of Galvani Bioelectronics, responsible for the company’s path to and delivery of bioelectronic medicines to patients. Before his appointment to lead Galvani Bioelectronics, he was the founding VP and head of Bioelectronics R&D at GSK, which he launched in 2013. There he managed the unit’s extensive research towards establishing the treatment potential, disease reach and technology requirements for bioelectronic medicines, working together with a network of research partners across academia and industry. During his time at GSK he also headed up the R&D Strategy Group and the Protein Degradation Discovery Performance Unit. Kris obtained his PhD in Molecular Biology at University of Cambridge, following an MSc in Chemical Engineering at Lund University, Sweden.

Jonathon Lobbins is the Chairman and Chief Executive Officer of Primasun where his focus is on leading the development and commercialization of solutions that enable healthcare providers to identify, diagnose, treat, manage, and improve outcomes for sleep based chronic disease including the over 50 million Americans living with sleep apnea. Most recently, Jonathon was the Vice President of Strategy and Business Development at Siemens Healthineers responsible for strategy, strategic alliances, and commercial scale up of new initiatives. His prior leadership experience includes 25 years across the medical device and electronics industries with key responsibilities spanning Engineering, Operations, Market Access, Strategy and Business Development. Jonathon earned his B.S Degree in Chemistry from Michigan State University, M.S. in Engineering from University of Florida and MBA from the Northwestern Kellogg School of Management.

Vindell Washington, M.D., M.S., is the Chief Clinical Officer of the Verily Health Platforms group and the interim CEO of Onduo. He focuses on strategies that will enable advanced technology solutions for healthcare transformation, engaging partners in developing tools and platforms for improving health outcomes and reducing costs of care. Vindell previously served as chief medical officer and EVP at Blue Cross Blue Shield of Louisiana, where he oversaw network operations and contracting, medical policy and quality, disease management, and pharmacy benefits. Prior to that, he was National Coordinator for Health Information Technology (ONC), where he provided high-level executive direction and leadership for ONC programs, operations and policies. Vindell received his medical degree from the University of Virginia and his M.S. degree in healthcare management from the Harvard University School of Public Health.

Denny is a veteran executive, having spent 35 years in healthcare financing and operations. Prior to serving as CEO of Coefficient, his background included a four-year tenure as CEO of Hixme, a digital health benefits platform for large employers, and a 20-year tenure with Wellpoint (Anthem), serving as CEO for a number of its nationwide insurance companies. In his earlier career, Denny served Deloitte Consulting for six years as a consultant in the insurance, benefits and healthcare industries, and he spent six years as chief engineer and general manager of the CTX division of IC Industries. Denny’s private equity board involvements have included Renal Ventures Management, Applied Merchant Systems, Westlake Davvar and Skyview Development. He has also held startup advisory and/or board positions with Outpatient, Focal Scan Systems, and Hixme. Denny’s public company board involvements have included Dole Food Company, Salem Communications Corp, Health Management, Inc. and Wellpoint/Anthem.

Dennis A. Ausiello, MD, is the Jackson Distinguished Professor of Clinical Medicine and director emeritus of the MD/PhD Program at Harvard Medical School. He is also chairman of Medicine emeritus and director of the Center for Assessment Technology and Continuous Health (CATCH) at the Massachusetts General Hospital (MGH). This center is a partnership among MGH, MIT, and Harvard University whose mission is to develop real-time assessment of human traits in wellness and disease. A graduate of Harvard and the University of Pennsylvania, Dennis is a nationally recognized leader in academic medicine who understands the needs for partnerships between the academy and industry.

Linda Avey is co-founder & CEO of Precise.ly, a precision medicine engine providing deep genetic insights to patients with chronic conditions. The company's goal is to identify disease subtypes leading to more precise diagnoses and treatments. In 2006, Avey co-founded 23andMe, the leading direct-to-consumer genetics company. The idea for 23andMe came during her tenure at Affymetrix and Perlegen Sciences, where she observed gaps in the US research model that could be solved through a web- and consumer-based approach. 23andMe now houses the world's largest genetic database with 80% of its participants powering the research mission. Prior to 23andMe, Linda had over 25 years' experience working with the biopharmaceutical and academic research industry.

Dimitri Azar, MD, MBA, is the Chief Executive Officer for Twenty/Twenty Therapeutics and former Dean of the University of Illinois College of Medicine. Dimitri is an ophthalmic surgeon who has made significant contributions to the treatment of corneal diseases and to advances in refractive surgery. He has served as a key adviser on Verily ophthalmic projects since 2014. Dimitri completed his residency and fellowship at the Massachusetts Eye and Ear Infirmary, Harvard Medical School. He was Professor of Ophthalmology at Harvard Medical School before joining the University of Illinois as Head of the Ophthalmology Department. Dimitri received his MD from American University of Beirut and his MBA from University of Chicago, Booth School of Business.

Hal V. Barron, MD, joined GSK as chief scientific officer and president, R&D on in January 2018. His previous role was president, R&D at Calico (an Alphabet-backed life sciences company). Prior to this, Hal was executive vice president, head of Global Product Development, and chief medical officer of Roche, responsible for all the products in the combined portfolio of Roche and Genentech. At Genentech, he was senior vice president of Development and chief medical officer. Hal was previously a non-executive director and chair of the Science & Technology Committee at Juno Therapeutics, Inc. He is associate adjunct professor, Epidemiology & Biostatistics, University of California, San Francisco. Hal holds a BS degree in Physics from Washington University in St. Louis and a medical degree from Yale University. He completed his training in Cardiology and Internal Medicine at the University of California, San Francisco.

Kathy Giusti, a multiple myeloma patient, is the founder and chief mission officer of the Multiple Myeloma Research Foundation (MMRF) and serves on its board of directors. Kathy has led the MMRF in establishing collaborative research models in the areas of tissue banking, genomics, and clinical trials that are dramatically accelerating the pace at which life saving treatments are brought to patients. She also leads the Kraft Precision Medicine Accelerator, a $20M endowed program at Harvard Business School (HBS) that is developing business models to speed breakthroughs in precision medicine for all cancers. She received her MBA from HBS and holds an honorary Doctorate from the University of Vermont.

Linda is the past SEVP and Chief Operating Officer at Manulife Financial (operating as John Hancock in the US) responsible for globally leading Technology, Advanced Analytics, Marketing, Innovation, Corporate Strategy and Corporate Development, Human Resources, Regulatory and Public Affairs, Global Resourcing and Procurement, and the Transformation Program. Prior to Manulife, Linda was the Executive Vice President of Digital, Payments and Cards at Royal Bank of Canada (RBC), responsible for Mobile and Online Banking, credit cards, co-brands, RBC Rewards, Merchant Solutions (Chair of Moneris Board of Directors), and Innovation for the retail bank. At RBC, she held a number of increasingly senior positions since joining in 2003.

Fabrizio Michelassi, MD, FACS, ESA (Hon.), SIC (Hon.), SACPNE (Hon.), is the Lewis Atterbury Stimson Professor of Surgery and Chairman of Surgery at Weill Cornell Medicine and Surgeon-in-Chief at New York Presbyterian/Weill Cornell Medical Center. A world-renowned gastrointestinal surgeon with a strong expertise in the surgical treatment of gastrointestinal and pancreatic cancers as well as inflammatory bowel disease, Dr. Michelassi has contributed new insight in the surgical treatment of pancreatic and colorectal cancers, ulcerative colitis and Crohn’s disease through research and participation in multiple clinical trials. A prolific author of more than 330 papers, book chapters and abstracts, he has edited a book on “Operative strategies in inflammatory bowel disease” and has produced fifteen instructional movies for surgeons on the surgical treatment of complications of Crohn’s disease and ulcerative colitis.

Phil Nelson is a director of Engineering in Google Research. He joined Google in 2008 and was previously responsible for a range of Google applications and geo services. In 2013, he helped found and currently leads the Google Accelerated Science team that collaborates with academic and commercial scientists to apply Google's knowledge and experience running complex algorithms over large data sets to important scientific problems. Phil graduated from MIT in 1985 where he did award-winning research on hip prosthetics at Harvard Medical School. Before Google, Phil helped found and lead several Silicon Valley start-ups in search (Verity), optimization (Impresse), and genome sequencing (Complete Genomics) and was also an entrepreneur in residence at Accel Partners.

Steve N. Oesterle is a venture partner at NEA and serves as a senior advisor to EQT Partners and Temasek Holdings. He is currently a board director at Baxter International and Reva Medical. He was formerly SVP for Medicine and Technology at Medtronic, and a member of its Executive Operating Committee for 14 years. He oversaw long term internal technology investments while participating in strategic corporate investments in emerging private companies. He also served as a member of Medtronic's Business Development and Strategy Committee that approved all corporate acquisitions. Steve graduated summa cum laude from Harvard and received his MD from Yale; he completed his residency at Massachusetts General Hospital. Following medical school, he completed a fellowship in Interventional Cardiology at Stanford and then served on the faculty at Stanford and Harvard Medical Schools and directed the Invasive Cardiology Services at Massachusetts General Hospital and Stanford.

Daniel D. Von Hoff, MD, FACP is currently physician in chief, distinguished professor Translational Research Division at TGen (Translational Genomics Research Institute) in Phoenix, Arizona. He is also chief scientific officer for HonorHealth Clinical Research Institute and the Virginia G. Piper Distinguished Chair for Innovative Cancer Research. He is the medical director of research at McKesson Specialty Healthcare and the scientific medical officer for US Oncology Research and leader of the Translational Oncology Program (TOP) specializing in phase I clinical trials done in the US Oncology Research network. Daniel is also currently the Senior Consultant-Clinical Investigations for City of Hope. He also holds an appointment as professor of Medicine, Mayo Clinic, Scottsdale, AZ.